JOHN D. DINGELL, MICHIGAN CHARMAN EMERITUS EDWARD J. MARKEY, MASSACHUSETTS RICK BOUCHER, VIRGINIA FRANK PALLONE, JR., NEW JERSEY BART GORDON, TENNESSEE BOSBY L RUSH, ILLINOIS ANNA G ESHOO, CALIFORNIA BART STUPAK, MICHIGAN ELIOT L. ENGEL, NEW YORK GENE GREEN, TEXAS DIANA DEGETTE, COLORADO VICE CHAIRMAN LOIS CAPPS, CALIFORNIA MIKE DOYLE, PENNSYLVANIA JANE HARIMAN, CALIFORNIA JAN BCHAKDWSKY, ILLINOIS CHARLES A. GONZALEZ, TEXAS JAY INSLEE, WASHINGTON TAMMY BALDWIN, WISCONSIN MIKE ROSS, ARKANEAS ANTHONY D. WEINER, NEW YORK JIM MATHEBON, UTAH G K BUTTERFELD, NORTH CAROLINA CHARLIE MELANCON, LDUISIANA JOHN BARROW, GEORGIA BARON P. HILL, INDIANA DORIS D. MATSUL CALIFORNIA DONNA CHRISTENSEN, VIRGIN ISLANDS KATHY CASTOR, FLORIDA JOHN SARBANES, MARYLAND CHRISTOPHER MURPHY, CONNECTICUT ZACHARY T. SPACE, OHIO JERRY MCNERNEY, CALIFORNIA BETTY SUTTON, OHIO REACE BRALEY, IDIAIA PETER WELCH, VERN

ONE HUNDRED ELEVENTH CONGRESS

## Congress of the United States House of Representatives

COMMITTEE ON ENERGY AND COMMERCE 2125 RAYBURN HOUSE OFFICE BUILDING WASHINGTON, DC 20515-6115

> MAJORTY (202) 225-2927 FACRIMILE (202) 225-2925 MINORITY (202) 225-3641

energycommerce.house.gov

February 27, 2009

Dr. John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285

Dear Dr. Lechleiter:

The Committee on Energy and Commerce and its Subcommittee on Oversight and Investigations are investigating the removal of Dr. Sanjay Kaul, M.D., M.P.H, from the Food and Drug Administration's advisory committee meeting on an anti-clotting drug, prasugrel.

Dr. Kaul, a cardiologist at Cedars-Sinai Heart Institute, is a voting member of FDA's Cardiovascular and Renal Drugs Advisory Committee. Before joining the advisory committee, Dr. Kaul had authored research abstracts questioning prasugrel's safety and effectiveness. According to FDA, Dr. Kaul submitted these abstracts and all other required information during FDA's conflict screening process before FDA selected him for the panel.<sup>1</sup>

According to press reports, the advisory committee met on February 3, 2009, to consider the new drug application for prasugrel. These accounts stated that Eli Lilly, the manufacturer of prasugrel, contacted FDA officials before the meeting to raise concerns about Dr. Kaul's participation in the advisory committee.<sup>2</sup> FDA officials then reportedly disinvited Dr. Kaul from the meeting due to an alleged "intellectual bias" against the drug.<sup>3</sup>

As part of our investigation, we request that Eli Lilly produce the following documents:

JOE BARTON, TEXAS

RALPH M. HALL, TEXAS
FRED UPTON, MICHGAN
CLUFF BTEARINS, FLORIDA
MATHAN DEAL, GEORGIA
EO WHITELD, KENTUCKY
JOHN SHRIKUS, ILLINOIS
JOHN SHRIKUS, ILLINOIS
JOHN B. SHADEGG, ARIZONA
ROY BLUNT, MISSOURI
STEVE BUYER, INDIANA
GEORGE RADANOVICH, CALIFORNIA
JOSEPH R PITTS, PENNSYLVANIA
MARY BUNDO MACK, CALIFORNIA
GREG WALDEN, OREGON
LEE TERRY, NEBRASKA
MIKE ROGERS, MICHIGAN
SUE WELKINS MYRICK, NORTH CAROLINA
JOHN SULLIYAN, OKCHOMA
TIM MURPHY, PENNSYLVANIA
MICHAEL C. SURGEBS, TEXAS
MARSHA BLACKBURN, TENNESSEE
PHL BINDIREY, GEORGIA
STEVE SCALISE, LOUISIANA

<sup>&</sup>quot;Mistakes" Made: FDA Acknowledges Lilly Phoned to Question Sanjay Kaul's Inclusion on Prasugrel Panel (Feb. 20, 2009) (online at www.theheart.org/article/943511.do).

<sup>&</sup>lt;sup>2</sup> FDA: "Mistake" Not To Include Doctor At Eli Lilly Drug Panel, Dow Jones Newswire (Feb. 23, 2009).

<sup>&</sup>lt;sup>3</sup> FDA Admits Error in Barring Doctor From Panel, Associated Press (Feb. 24, 2009).

Dr. John C. Lechleiter February 27, 2009 Page 2

- All documents and communications, including email, to or from officials at FDA, Eli
  Lilly, or any other person or entity relating to Dr. Kaul; and
- 2. A log of communications, including phone calls, to or from officials at FDA, Eli Lilly, or any other person or entity relating to Dr. Kaul's research on prasugrel or his participation in the February 3, 2009, advisory committee meeting, including the date of the communication, the names of the participants, and a description of the matters discussed.

Please produce these documents by Friday, March 13, 2009. An attachment to this letter provides additional information on how to respond to the Committee's request. If you have any questions regarding this request, please contact Michael Gordon or Stacia Cardille with Committee staff at (202) 226-2424.

Sincerely,

Henry A Waxman

Bart Stupak Chairman

Subcommittee on Oversight and Investigations

## Enclosure

cc: Joe Barton

Ranking Member

Committee on Energy and Commerce

Greg Walden
Ranking Member
Subcommittee on Oversight and
Investigations